13D Filing: Levin Capital Strategies and Fluidigm Corp (FLDM)

Page 1 of 21

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Levin Capital Strategies 0 8,274,483 0 11,395,014 11,395,014 29.6%
Levin Capital Strategies GP 0 8,274,483 0 11,395,014 11,395,014 29.6%
Levin Capital Trilogy Master Fund, Ltd 0 82,884 0 82,884 82,884 Less%
LCS 0 82,884 0 82,884 82,884 Less%
Levcap Alternative Fund 0 56,820 0 56,820 56,820 Less%
LCS Event Partners 0 56,820 0 56,820 56,820 Less%
Safinia Partners 0 19,818 0 19,818 19,818 Less%
LCS L S 0 19,818 0 19,818 19,818 Less%
John A. Levin 0 8,331,303 0 11,395,014 11,395,014 29.6%

Follow John A. Levin's Levin Capital Strategies

Page 1 of 21 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Fluidigm Corporation

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

34385P108

(CUSIP Number)

John A. Levin

Levin Capital Strategies, L.P.

595 Madison Avenue, 17th Floor

New York, NY 10022

(212) 259-0800

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 10, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f)
or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

1

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 1 of 21